In particular, ALDH1A3 targeting has been investigated for its potential clinical applications in several cancer types, including metastatic breast cancer [16], non-small-cell lung cancer (NSCLC) [17] and mesenchymal subtype gliomas [18]. The gene discussed is ALDH1A3; the disease is non-small cell lung carcinoma.